Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

Background The immunosuppressive desmoplastic stroma of pancreatic cancer represents a major hurdle to developing an effective immune response. Preclinical studies in pancreatic cancer have demonstrated promising anti-tumor activity with Bruton tyrosine kinase (BTK) inhibition combined with programm...

Descripció completa

Dades bibliogràfiques

Autors principals:	Al B Benson, Anirban Maitra, Milind Javle, Michael Overman, Richard E Davis, Pankaj Vats, Chandan Kumar-Sinha, Lianchun Xiao, Niharika B Mettu, Edwin R Parra, Charles D Lopez, Veerendra Munugalavadla, Priti Patel, Lin Tao, Sattva Neelapu
Format:	Artigo
Idioma:	Inglês
Publicat:	BMJ Publishing Group 2020-05-01
Col·lecció:	Journal for ImmunoTherapy of Cancer
Accés en línia:	https://jitc.bmj.com/content/8/1/e000587.full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!